GUMDROP : AOH - FIRSTANA- Randomized, Open Label, Study Comparing Cabazitaxel at 25 mg per m2 and at 20 mg per m2 every 3 weeks to Docetaxel in Combination with Prednisone in Patients with mCRPC not Pretreated with Chemotherapy
Created by Dipak Dahal, last modified by Nancy Dawson on May 02, 2013
Description: | First Line Chemotherapy with Cabazitaxel Vs Docetaxel with Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following – - Increase in measurable disease (RECIST 1.1) and/ or
- Appearance of new lesions, including those on bone scan (> new lesions on 2 sequential bone scans if PD diagnosed on bone scan only) consistent with progressive prostate cancer, and/ or
- Rising PSA defined as 2 sequential increases above a previous lowest reference value. Each value must be obtained at least 1 weak apart. A PSA value of at least 2 ng/mL is required at study entry.
|
|---|
Link: | http://clinicaltrials.gov/ct2/show/NCT01308567 |
Site: | Associates in Oncology Hematology (AOH) - Rockville, MD
Phone: 301 424 6231 |
Principal Investigator: | Manish Agrawal, MD |